(CMMB)
NCM – Real Time Price. Currency in USD
1.46
-0.09 (-5.81%)
At close: Mar 27, 2026, 4:00 PM EDT
1.50
+0.04 (2.74%)
After-hours: Mar 27, 2026, 4:28 PM EDT
Get all premium features to the best stock analysis tool
NCM – Real Time Price. Currency in USD
1.46
-0.09 (-5.81%)
At close: Mar 27, 2026, 4:00 PM EDT
1.50
+0.04 (2.74%)
After-hours: Mar 27, 2026, 4:28 PM EDT
Chemomab Therapeutics Ltd., a clinical-stage biotechnology company, focuses on the discovery and development of therapeutics for the treatment of fibrotic and inflammatory diseases in the United States. Its lead product candidate is Nebokitug, a humanized monoclonal antibody attenuates the basic function of CCL24 that has completed phase 2 clinical trial for the treatment of primary sclerosing cholangitis (PSC); and is in phase 2 clinical trial to treat systemic sclerosis (SSc). Chemomab Therapeutics Ltd. was founded in 2011 and is based in Tel Aviv-Yafo, Israel.
| Name | Position |
|---|---|
| Dr. Adi Mor George Ph.D. | Co-Founder, Chief Scientific Officer, CEO & Executive Director |
| Date | Type | Document |
|---|---|---|
| 2026-03-19 | 6-K | zk2634872.htm |
| 2025-11-21 | 6-K | zk2534057.htm |
| 2025-08-22 | 6-K | zk2533691.htm |
| 2025-08-14 | 6-K | zk2533584.htm |
| 2025-07-25 | 6-K | zk2533479.htm |
| 2025-07-01 | 6-K | zk2533404.htm |
| 2025-05-27 | 6-K | zk2533263.htm |
| 2025-04-15 | 6-K | zk2533017.htm |
| 2025-04-04 | 20-F | zk2532902.htm |
| 2025-03-27 | 6-K | zk2532931.htm |